Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1884 studies found for:    Blood Coagulation Disorders: Clinical Trials
Show Display Options
Rank Status Study
21 Completed
Has Results
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Condition: HIV-1 Infection
Interventions: Drug: atorvastatin;   Drug: placebo for atorvastin
22 Completed
Has Results
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency
Intervention: Drug: catridecacog
23 Completed Evaluation of the TICCS Capacity to Identify Trauma Patients With Acute Coagulopathy and Massive Bleeding
Conditions: Multiple Trauma;   Massive Bleeding;   Early Complication of Trauma
Intervention:
24 Recruiting A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Interventions: Drug: N9-GP;   Drug: ALPROLIX®
25 Completed Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
Conditions: Coronary Heart Disease;   Coagulation Disorder
Intervention: Drug: Anfibatide
26 Unknown  Study Using Plasma for Patients Requiring Emergency Surgery
Conditions: Hemorrhagic Shock;   Blood Coagulation Disorders;   Blood Products;   Trauma;   Ruptured AAA
Intervention: Drug: Human Plasma
27 Completed Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.
Conditions: Blood Coagulation Disorders;   Hemorrhage
Intervention: Drug: Human fibrinogen concentrate
28 Terminated
Has Results
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
Conditions: Acquired Bleeding Disorder;   Trauma
Interventions: Drug: eptacog alfa (activated);   Drug: placebo
29 Active, not recruiting A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A.
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
30 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
31 Terminated A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Healthy
Intervention: Drug: NNC172-2021
32 Completed Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: nonacog beta pegol
33 Withdrawn Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
Conditions: Acquired Bleeding Disorder;   Trauma
Intervention: Drug: activated recombinant human factor VII
34 Not yet recruiting Management of Coagulopathy in Cirrhotic Patients Undergoing Invasive Procedures
Conditions: Liver Cirrhosis;   Coagulopathy
Intervention: Other: Thromboelastography based protocol
35 Completed Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients
Conditions: Trauma;   Coagulopathy
Interventions: Drug: Freezed-dried plasma;   Drug: Fresh-frozen plasma
36 Completed Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Conditions: Acquired Bleeding Disorder;   Dengue Haemorrhagic Fever
Interventions: Drug: activated recombinant human factor VII;   Drug: placebo
37 Completed Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Other: No treatment given
38 Completed
Has Results
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: vatreptacog alfa (activated);   Drug: eptacog alfa (activated)
39 Completed Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation
Conditions: Acquired Bleeding Disorder;   Bleeding During/Following Surgery
Interventions: Drug: activated recombinant human factor VII;   Drug: placebo
40 Completed A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B;   Healthy
Interventions: Drug: activated recombinant human factor VII, long acting;   Drug: placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.